500 Million or 1 in 10 Adults Will Have Diabetes by 2030

The International Diabetes Federation (IDF) is the umbrella organization of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950, and IDF’s mission is to promote diabetes care, prevention, and a cure worldwide.

New figures from the 5th edition Diabetes Atlas (see indicate that the number of people living with diabetes is expected to rise from 366 million in 2011 to 552 million by 2030. IDF also estimates that as many as 183 million people are unaware that they have diabetes.

The release of these figures follows the September meeting of 193 Heads of State and government officials at the UN High Level Meeting in New York to agree on a Political Declaration on Non-Communicable Diseases (NCDs) including diabetes. This marks a major milestone for diabetes and other NCDs. Ann Keeling, CEO, International Diabetes Federation (IDF) and Chair of the NCD Alliance stated:

“World leaders have recognised the magnitude and impact of these diseases and the urgent need for action … The Declaration will accelerate international progress on diabetes and NCDs, saving millions of people from preventable death and disability.”

ALR Technologies (ALRT)

The growth in the diabetic market should be beneficial for the  Health-e-Connect (HeC) System, which is the principal product of ALR Technologies (OTCBB: ALRT).  HeC is a web-based platform designed to assist healthcare providers caring for diabetes patients improve the compliance to and management of patient care plans through remote monitoring.  Moreover, the system offers a solution to potentially reduce waste and cut costs to the healthcare system by electronically documenting or counting actual blood glucose test strip usage. Blood glucose test strips are a key element of self-monitoring of blood glucose (SMBG) and billions of dollars are spent each year on test strips for patients with diabetes. Through a unique communications channel, the ALRT HeC System’s platform also enables test strip suppliers to offer extra support to patients by encouraging them to be more compliant with their diabetes treatment plans.  Adherence to prescribed treatment plans should improve health outcomes and reduce long-term healthcare costs by helping to prevent diabetes complications. The ALRT HeC System was successfully used in a clinical trial by type 2 diabetes patients on insulin as part of an intensive glucose monitoring program.

The HeC System supports data uploads from blood glucose meters manufactured by Abbott Diabetes Care, Bayer Diabetes Care, LifeScan Inc. (a Johnson & Johnson Company) and Roche Diabetes Care.

Down the road, ALRT plans to expand this platform to serve cover with other chronic diseases.

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated twenty thousand dollars per month for three months of consultation and journalism services and to manage a comprehensive investor relations/awareness program by ALR Technologies.  Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial(0)

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome. With the success seen by

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen(0)

One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact.

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract

Sunvalley Solar Shares Rise from Bottom on Solar Installation Contract(0)

Shares of Sunvalley Solar, Inc. (OTCBB: SSOL) are rising in trading Monday morning after the solar power technology company disclosed a new contract to 87.5-kilowatt solar system installation contract from Corporate Logistics in City of Industry, California. The contract is for a system capable of generating 131,146 kilowatt hours of electrical power each year, utilizing

Men’s Health Features Naked Brand Group Line of Underwear

Men’s Health Features Naked Brand Group Line of Underwear(0)

Naked Brand Group, Inc. (OTCQB: NAKD) said Friday that its Naked Boxer Brief has been selected by Men’s Health for its online guide, “Affordable Spring Style Guide 100 under $100.”  The guide was published on on March 20.  This is the second time the company has been featured in the men’s mag in as

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials

Sunshine Biopharma Meeting with CMOs to Manufacture Drug for Breast Cancer Trials(0)

Sunshine Biopharma Inc. (OTCQB: SBFM) reported on Thursday that it is in negotiations with Contract Manufacturing Organizations, or CMOs, as the next progression towards the anticipated clinical trials of its flagship cancer drug, Adva-27a, against multi-drug resistant forms of breast cancer. The trials are scheduled to be hosted by the leading cancer center Jewish General

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.